Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 28;5(9):114.
doi: 10.3390/children5090114.

High-Risk Neuroblastoma Treatment Review

Valeria Smith  1 , Jennifer Foster  2
Affiliations
Review

High-Risk Neuroblastoma Treatment Review

Valeria Smith et al. Children (Basel). .

Abstract

Neuroblastoma is the most common extracranial solid tumor in children. One subset, high-risk neuroblastoma, is very difficult to treat and requires multi-modal therapy. Intensification of therapy has vastly improved survival rates, and research is focused on novel treatments to further improve survival rates. The current treatment schema is divided into three stages-induction, consolidation, and maintenance. This review serves as an overview of the current treatment for high-risk neuroblastoma and a glimpse at current research for future therapy.

Keywords: diagnosis; high-risk neuroblastoma; neuroblastoma; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
High-risk neuroblastoma treatment overview.
See this image and copyright information in PMC

References

    1. Brodeur G., Hogarty M., Bagatell R., Mosse Y., Maris J. Neuroblastoma. In: Pizzo P., Poplack D., editors. Principles and Practice of Pediatric Oncology. 7th ed. Wolters Kluwer; Philadelphia, PA, USA: 2016. pp. 772–798.
    1. Cohn S.L., Pearson A.D.J., London W.B., Monclair T., Ambros P.F., Brodeur G.M., Faldum A., Hero B., Iehara T., Machin D., et al. The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report. J. Clin. Oncol. 2009;27:289–297. doi: 10.1200/JCO.2008.16.6785. - DOI - PMC - PubMed
    1. Monclair T., Brodeur G.M., Ambros P.F., Brisse H.J., Cecchetto G., Holmes K., Kaneko M., London W.B., Matthay K.K., Nuchtern J.G., et al. The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report. J. Clin. Oncol. 2009;27:298–303. doi: 10.1200/JCO.2008.16.6876. - DOI - PMC - PubMed
    1. Pinto N.R., Applebaum M.A., Volchenboum S.L., Matthay K.K., London W.B., Ambros P.F., Nakagawara A., Berthold F., Schleiermacher G., Park J.R., et al. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J. Clin. Oncol. 2015;33:3008–3017. doi: 10.1200/JCO.2014.59.4648. - DOI - PMC - PubMed
    1. Louis C.U., Shohet J.M. Neuroblastoma: Molecular Pathogenesis and Therapy. Annu. Rev. Med. 2015;66:49–63. doi: 10.1146/annurev-med-011514-023121. - DOI - PMC - PubMed